查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858271

思覺失調症藥物市場：2025-2032年全球預測（按類型、治療類別、作用機制、劑型、最終用戶、患者環境和患者群體分類）

Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，思覺失調症治療市場將成長至 91.4 億美元，複合年成長率為 5.63%。

關鍵市場統計數據
基準年 2024 58.9億美元
預計年份：2025年 62.1億美元
預測年份 2032 91.4億美元
複合年成長率 (%) 5.63%

思覺失調症：重點關注臨床挑戰、不斷發展的治療模式以及以患者為中心的創新需求

思覺失調症是神經精神病學中最複雜、最重要的領域之一，其治療方法的發展與臨床知識的進步、患者期望的改變以及法規結構的完善同步進行。本導論旨在透過概述臨床需求、治療方法方法的多樣性以及正在重塑診斷和治療路徑的技術和科學趨勢的融合，幫助讀者了解當前的治療格局。

臨床醫師和研究人員持續面臨症狀表現、治療反應和合併症的差異，凸顯了採取全面照護方法的必要性。過去十年，治療選擇已從傳統的口服抗精神病藥物擴展到長效注射劑、神經調控技術和輔助性心理社會干預，每種方法的療效、依從性和耐受性各不相同。同時，生物標記、影像學和數位化評估工具的進步提高了診斷準確性，並使治療方案的調整更加及時。

重要的是，患者及其看護者越來越傾向於尋求能夠兼顧症狀控制和生活品質（QOL）的治療方法，例如認知功能、社會融入和工作能力。因此，創新者和醫療服務提供者正致力於整合藥物治療、心理療法和數位化支持，並促進醫院、門診和社區等不同醫療環境中的協作式醫療服務。本報告透過闡明這些潛在趨勢，並重點關注臨床需求、科學進步和商業性機會之間的交集，為更深入的分析奠定了基礎。

識別將重塑思覺失調症治療的變革性轉變，包括精準精神病學、數位療法、長效製劑和整合式醫療服務模式。

思覺失調症的治療格局正在經歷一系列變革，這些變革正在改變治療方法的研發、實施和評估方式。精準精神病學正從概念走向實踐，其方法是透過生物標記、臨床表現和治療反應模式對患者進行分層。因此，研發計畫的設計越來越傾向於針對更細分的、具有生物學依據的亞群，臨床研發策略也更加重視適應性研究設計和富含生物標記的隊列，以加速概念驗證。

同時，包括緩釋性注射劑和植入式的長效藥物正在重新定義藥物依從性模式，並改變社區和醫療機構的照護流程。數位療法和遠端監測工具為症狀追蹤和早期復發檢測創造了新的切入點，從而能夠進行更積極主動的干涉。此外，將藥物治療與結構化心理治療、認知矯正和社會支持相結合的綜合護理模式正日益受到重視，因為它們關注的是患者最關心的功能性結果。

監管機構正採取更靈活的醫療設備和組合產品核准途徑來應對這些變化，而支付方也開始認知到減少住院次數並帶來持續功能改善的干涉措施的長期價值。總而言之，這些變化為多學科合作創造了機遇，並要求相關人員重新思考臨床試驗設計、商業化路徑和上市後證據的生成。

評估2025年美國關稅對思覺失調症藥物供應鏈、臨床營運和國際合作動態的累積影響

2025年推出的政策和貿易措施對思覺失調症藥物生態系統產生了累積影響，改變了成本結構、供應鏈韌性和跨國合作動態。關稅調整影響了活性藥物原料藥、專用診斷設備和某些醫療設備組件的分銷，迫使製造商和經銷商重新評估籌資策略和庫存管理，以減輕潛在的中斷。為此，許多機構加快了近岸外包，並使其供應商網路多元化，以確保生產的連續性並維持臨床試驗的進度。

除了製造業之外，關稅也透過影響國際合作的經濟效益，對研發產生了連鎖反應。申辦方在考慮全球臨床試驗地點時，重新評估了其選址標準，將總營運成本和物流複​​雜性納入考量。同時，不斷增加的成本壓力促使企業採取措施提高營運效率，包括精簡臨床供應鏈、最佳化批量規模以及利用靈活的契約製造關係。

從支付方和提供方的角度來看，投入成本的變化促使各方重新重視價值證明和基於結果的契約，以期在控制預算的同時維持醫療服務的可及性。此外，價格環境也凸顯了監管協調和與政策制定者進行策略合作的重要性，以確保患者能夠及時獲得創新治療方法。總而言之，這些趨勢強化了商業策略和供應策略協調一致以維持治療藥物供應和保障醫療服務連續性的必要性。

詳細的細分分析揭示了思覺失調症治療中治療方法類型、治療領域、作用機制、劑型、最終用戶、臨床環境和人口統計學方面的細微差別

對細分市場的深入理解有助於闡明治療方案的發展和服務提供如何與患者需求和臨床情況相符。治療方法依類型分為非藥物療法和藥物療法。非藥物療法包括認知行為療法、電痙攣療法和家庭療法，而藥物療法則涵蓋注射劑和口服藥物，每種療法在依從性、給藥和監測方面都面臨著不同的挑戰。

依治療類別分類，產品組合包括抗精神病藥物、情緒穩定劑和選擇性血清素再回收抑制劑。抗精神病藥物進一步分為第一代和第二代藥物，這一區分指南副作用管理、耐受性和長期安全性方面的決策。作用機轉也是一項重要的分類標準，涵蓋多巴胺受體拮抗劑、麩胺酸調節劑以及血清素和多巴胺活性調節劑，指南以改善難治性症狀和認知障礙為目標的標靶研發策略。

製劑類型對於患者的用藥便利性和藥物動力學都至關重要，其範圍涵蓋從插片和貼片到液體和固態片劑，並影響患者的依從性和臨床監測。最終使用者包括居家醫療、醫院、精神科診所和研究機構，這些機構共同決定了通路、培訓需求和支援模式。患者就診環境分為住院和門診，影響治療方案的選擇和臨床監測的強度。此外，患者群體又細分為成人、老年和兒童患者，每個亞組都有其獨特的治療重點、安全考量和監管途徑。全面考慮患者群體細分有助於相關人員調整開發計劃、商業策略和醫療服務模式，使其與不同的臨床和營運實際情況相適應。

影響思覺失調症藥物取得、研究和商業化的區域趨勢和戰略要務（美洲、歐洲、中東和非洲、亞太地區）

區域趨勢對思覺失調症藥物的研發、核准、報銷和應用有顯著影響。了解這些差異對於制定有效的全球策略至關重要。在美洲，臨床研發基礎設施完善、支付方環境相對成熟，以及數位醫療解決方案日益普及，都為新治療方法的快速推廣提供了支持。然而，都市區地區在醫療資源取得方面的差異以及社區服務的差異，需要製定個人化的分發和推廣策略。

歐洲、中東和非洲地區各國的監管路徑和醫療保健資金籌措模式差異顯著，導致准入條件和實施時間各不相同。許多地區高度重視衛生技術評估 (HTA) 和療效比較證據，尤其注重可靠的真實世界數據和長期療效研究。此外，某些市場的醫療資源限制凸顯了培訓計畫和與當地醫療機構合作的重要性，以確保複雜治療方法的合理應用。

在亞太地區，臨床研究的快速投入、強大的生產能力以及日益普及的數位醫療，為創新和規模化發展創造了有利環境。然而，打入市場策略必須考慮不同的監管要求、報銷環境以及與心理健康相關的文化因素。區域洞察表明，針對監管、證據生成和商業部署採取差異化策略，並充分考慮當地的臨床實踐和醫療體系優先事項，將有助於實現最永續的患者可及性和商業性效益。

思覺失調症治療領域主要企業的策略與競爭趨勢：聚焦夥伴關係、產品線多元化、數位整合與病人參與策略

在思覺失調症治療領域，各公司之間的競爭日益激烈，主要體現在對治療方法創新、策略聯盟和綜合護理解決方案的關注。成熟的生物製藥公司持續投資於分子最佳化、製劑改進和現有療法的生命週期管理，而新興的生物技術公司則專注於新型作用機制和生物標記主導的候選藥物，以應對難治性患者群體。

同時，科技公司和數位健康領域的新興參與企業正在開發用於症狀監測、藥物依從性支持和認知改善的輔助平台，這不僅拓寬了競爭格局，也為跨行業合作創造了機會。合約研究組織 (CRO) 和專業生產合作夥伴在提供製劑放大生產和監管申報方面的專業知識方面發揮關鍵作用，從而縮短了新治療方法進入臨床試驗的時間。經營模式正朝著許可、合作開發和策略性收購相結合的方向轉變，使企業能夠整合互補能力並降低研發風險。

從商業性角度來看，企業優先考慮能夠證明產品具有顯著功能性益處的證據，透過基於績效的合約與支付方建立聯繫，並建立完善的患者支援計劃，以提高治療依從性和患者滿意度。那些能夠將研發重點與實際臨床需求結合，並投資於可擴展的商業化平台和醫護人員培訓的經營團隊，將更有能力在創造價值的同時改善病患療效。

為行業領導者提供切實可行的建議，以加速思覺失調症治療領域的創新，確保供應彈性，向支付方證明價值，並改善患者預後

產業領導者應採取一系列協同行動，將科學進步轉化為持續的臨床和商業性效益。首先，各機構應優先投資於長效製劑和聯合治療，以提高患者依從性並降低復發率，同時制定嚴謹的證據方案，重點關注臨床醫生和支付方重視的功能性結果。其次，領導者應將數位化工具融入研發流程和診療路徑，以支援遠端監測、早期復發檢測和個人化依從性干預，從而增強不同醫療機構間診療的連續性。

第三，必須將供應鏈韌性作為策略重點。這包括供應商多元化、區域製造夥伴關係以及製定緊急時應對計畫，以減輕供應中斷及其對患者照護的影響。第四，商業機構應儘早與支付方接洽，協商利用真實世界數據和衛生經濟學模型評估長期價值和減少急診護理利用的報銷框架。第五，與學術機構、患者權益倡導團體和行為健康服務提供者建立合作關係，將有助於創新技術快速應用於日常實踐，並確保干預措施能夠響應實際經驗。

最後，各機構應採取適應性強的監管和臨床開發策略，包括利用生物標記、適應性設計和可操作的終點指標來有效證明療效。透過協調研發、商業和營運等各職能部門的工作，企業領導者得以在複雜的治療環境中，既改善病患預後，又實現競爭優勢。

本分析採用了一套嚴謹的調查方法，詳細說明了主要研究和次要研究、相關利益者訪談、臨床證據綜合以及資料檢驗方法。

本執行摘要的分析採用了混合方法研究，將質性研究結果與系統性證據綜合相結合，以確保研究結果的穩健性和相關性。主要研究包括對臨床醫生、支付方代表、臨床營運總監和患者權益倡導團體進行結構化訪談，以確定第一線挑戰、實施障礙和證據產生的優先事項。這些訪談有助於確定關鍵問題，並突顯哪些領域最需要收集更多資料。

我們的二次研究整合了同行評審文獻、監管指導文件、臨床試驗註冊資訊和產品標籤，以繪製治療機制、安全訊號和核准途徑。此外，我們也分析了試驗活動和研發管線訊息，以識別治療方法趨勢和研發瓶頸。跨資訊來源的資料三角驗證支持了我們研究結果的交叉檢驗，並有助於調和相關利益者觀點與已發表證據之間的差異。

透過預先設定的納入標準、對證據來源的定性評估以及與臨床專家進行反覆審查以檢驗，確保了分析的嚴謹性。研究明確承認了數據可用性的區域差異和不斷變化的法規環境等局限性，並在適當情況下應用了敏感性分析來檢驗假設。總體而言，該調查方法建構了一個思覺失調症，可為策略決策提供支援。

綜合洞察整合了臨床、商業性和監管趨勢，以指南策略決策，並優先考慮以患者為中心的思覺失調症治療開發。

總之，思覺失調症藥物治療領域呈現出科學創新、治療模式變革和複雜商業性動態的特點，這些因素共同為相關人員創造了機遇，同時也帶來了責任。藥理學、數位醫療和社會心理介入的進步為改善症狀管理和功能恢復提供了切實的前景，但要取得持續進展，需要協調一致的循證醫學證據、適應性強的監管合作以及以患者為中心的服務提供。

此外，供應鏈中斷和政策變化等外部壓力凸顯了策略韌性和營運靈活性的重要性。整合多元治療方法、展現實際價值並促進整個醫療生態系統夥伴關係的機構，將更有能力應對不確定性，同時擴大有效治療的覆蓋範圍。最終，專注於對患者至關重要的結果——認知功能、社會融入和長期穩定性——將成為成功創新和公平實施的基石，並將指導未來在該領域的投資和合作。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 思覺失調症治療流程中個人化藥物基因體學方法的出現
  • 快速採用數位治療方法和人工智慧驅動的監測平台來預防復發
  • 人們對長效注射劑的興趣日益濃厚，以提高患者依從性。
  • 為難治性思覺失調症患者族群開發新型麩胺酸受體調變器
  • 增加針對思覺失調症神經發炎的抗發炎藥物的投資
  • 整合真實世界證據研究以支持標籤和報銷決策

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章思覺失調症治療藥物市場（按類型分類）

  • 非藥物療法
    • 認知行為治療（CBT）
    • 電痙攣療法（ECT）
    • 家庭治療
  • 藥物治療
    • 注射藥物
    • 口服藥物

第9章思覺失調症治療藥物市場（依治療類別分類）

  • 抗精神病藥物
    • 第一代抗精神病藥物
    • 第二代抗精神病藥物
  • 情緒穩定劑
  • 選擇性血清素再回收抑制劑

第10章思覺失調症治療藥物市場依作用機制分類

  • 多巴胺受體拮抗劑
  • 麩胺酸調變器
  • 血清素和多巴胺活性調節劑

第11章思覺失調症劑型分類）

  • 插片和補丁
  • 液體
  • 固態片劑

第12章思覺失調症治療藥物市場（依最終用戶分類）

  • 居家醫療環境
  • 醫院
  • 精神病診所
  • 研究所

第13章思覺失調症治療藥物市場（依病患環境分類）

  • 住院治療
  • 門診治療

第14章 按患者群體分類的思覺失調症治療藥物市場

  • 成年患者
  • 老年患者
  • 兒科患者

第15章 各地區思覺失調症治療藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章思覺失調症治療藥物市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國思覺失調症治療藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Acadia Pharmaceuticals Inc.
    • Alkermes Plc
    • Amneal Pharmaceuticals, LLC
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • BioXcel Therapeutics, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol Myers Squibb Company
    • Cipla Limited
    • Delpor, Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • Gedeon Richter Plc
    • GlaxoSmithKline plc.
    • Glenmark Pharmaceuticals Limited
    • Johnson & Johnson Services, Inc.
    • Lundbeck A/S
    • Lupin Limited
    • Luye Pharma Group Ltd
    • Lyndra Therapeutics Inc
    • Meiji Holdings Co., Ltd.
    • Merck & Co., Inc.
    • Neurocrine Biosciences, Inc.
    • Novartis AG
    • Otsuka Holdings Co., Ltd.
    • Pfizer Inc.
    • Reviva Pharmaceuticals Holdings, Inc.
    • Sanofi SA
    • Sumitomo Pharma Co., Ltd.
    • Sun Pharmaceutical Industries Limited
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Torrent Pharmaceuticals Ltd.
    • Vanda Pharmaceuticals Inc.
Product Code: MRR-8E22B61932B8

The Schizophrenia Therapeutics Market is projected to grow by USD 9.14 billion at a CAGR of 5.63% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.89 billion
Estimated Year [2025] USD 6.21 billion
Forecast Year [2032] USD 9.14 billion
CAGR (%) 5.63%

A concise overview of schizophrenia therapeutics highlighting clinical challenges, evolving treatment paradigms, and the imperative for patient-centered innovation

Schizophrenia remains one of the most complex and consequential areas within neuropsychiatry, and therapeutics development has advanced alongside evolving clinical understanding, patient expectations, and regulatory frameworks. This introduction orients readers to the current therapeutic landscape by summarizing the clinical imperatives, the diversity of treatment modalities, and the converging technological and scientific trends that are reshaping diagnostic and therapeutic pathways.

Clinicians and researchers continue to confront heterogeneity in symptom presentation, treatment response, and comorbidity, which together underscore the need for a multifaceted approach to care. Over the past decade, treatment options have expanded beyond traditional oral antipsychotics to include long-acting injectables, neuromodulation techniques, and adjunctive psychosocial interventions, each offering distinct efficacy, adherence, and tolerability profiles. Simultaneously, advancements in biomarkers, imaging, and digital assessment tools are improving diagnostic precision and enabling more timely therapeutic adjustments.

Importantly, patients and caregivers increasingly demand treatments that balance symptom control with quality-of-life considerations such as cognitive function, social integration, and employment capacity. As a result, innovators and providers are aligning around strategies that integrate pharmacology, psychotherapy, and digital supports, and that foster coordinated care across hospital, outpatient, and community settings. This report sets the stage for deeper analysis by clarifying these foundational dynamics and highlighting where clinical need, scientific progress, and commercial opportunity intersect.

Identifying transformative shifts reshaping schizophrenia care including precision psychiatry, digital therapeutics, long-acting modalities, and integrated care delivery models

The landscape of schizophrenia therapeutics is undergoing a series of transformative shifts that alter how treatments are developed, delivered, and evaluated. Precision psychiatry is moving from concept to practice through efforts to stratify patients by biomarkers, phenomenology, and treatment response patterns. As a consequence, development programs are increasingly designed to target narrower, biologically informed subpopulations, and clinical development strategies emphasize adaptive trial designs and biomarker-enriched cohorts to accelerate proof of concept.

At the same time, long-acting modalities, including extended-release injectables and implantable formulations, are redefining adherence paradigms and altering care workflows in both community and institutional settings. Digital therapeutics and remote monitoring tools are creating new touchpoints for symptom tracking and early relapse detection, thereby enabling more proactive interventions. Moreover, integrated care models that combine pharmacological treatment with structured psychotherapies, cognitive remediation, and social supports are gaining traction because they address functional outcomes that patients value most.

Regulatory agencies are responding with more flexible pathways for devices and combination products, and payers are beginning to recognize the long-term value of interventions that reduce hospitalization and improve sustained functioning. Taken together, these shifts create opportunities for interdisciplinary collaboration and require stakeholders to rethink clinical trial design, commercialization pathways, and post-market evidence generation.

Assessing the cumulative impact of United States tariffs in 2025 on schizophrenia therapeutic supply chains, clinical operations, and international collaboration dynamics

Policy and trade measures introduced in 2025 have exerted a cumulative influence on the schizophrenia therapeutics ecosystem by altering cost structures, supply chain resilience, and cross-border collaboration dynamics. Tariff adjustments affected the flow of active pharmaceutical ingredients, specialized diagnostic equipment, and certain device components, prompting manufacturers and distributors to reassess sourcing strategies and inventory management to mitigate potential disruptions. In response, many organizations accelerated nearshoring and diversified supplier networks to preserve manufacturing continuity and maintain clinical trial timelines.

Beyond manufacturing, tariffs have implications for research and development partnerships by influencing the economics of international collaboration. Sponsors weighing global trial sites reassessed site selection criteria to account for total cost of operations and logistics complexity. Simultaneously, heightened cost pressures stimulated operational efficiency efforts, including streamlining clinical supply chains, optimizing batch sizes, and leveraging contract manufacturing relationships with greater flexibility.

From the payer and provider perspective, changes in input costs encouraged renewed emphasis on value demonstration and outcomes-based contracting, as institutions seek to preserve access while managing budgets. Moreover, the tariff environment highlighted the importance of regulatory harmonization and strategic engagement with policy makers to ensure that patients continue to receive timely access to innovative therapies. Overall, these dynamics reinforced the need for coordinated commercial and supply strategies to sustain therapeutic availability and protect continuity of care.

Deep-dive segmentation insights that unpack therapy types, therapeutic classes, mechanisms, formulations, end users, care settings, and demographic nuances for schizophrenia care

A nuanced understanding of segmentation illuminates how therapeutic development and service delivery align with patient needs and clinical contexts. Based on type, treatments split into non-pharmacological therapies and pharmacological therapies, where non-pharmacological approaches include therapies such as cognitive-behavioral therapy, electroconvulsive therapy, and family therapy, and pharmacological approaches encompass both injectable medications and oral medications, each carrying distinct implications for adherence, administration, and monitoring.

When viewed by therapeutic class, the portfolio includes antipsychotics, mood stabilizers, and selective serotonin reuptake inhibitors, with antipsychotics further categorized into first-generation and second-generation agents; these distinctions inform decisions around side-effect management, tolerability profiles, and long-term safety considerations. Mechanism of action also provides a critical lens for segmentation, covering dopamine receptor antagonists, glutamate modulators, and serotonin dopamine activity modulators, and guiding targeted development strategies that aim to address refractory symptoms or cognitive deficits.

Formulation type matters for both patient convenience and pharmacokinetics, ranging from inserts and patches to liquid solutions and solid tablets, and influencing adherence patterns and clinical monitoring. End users span homecare settings, hospitals, mental health clinics, and research institutes, which collectively determine distribution channels, training needs, and support models. Patient settings dichotomize into inpatient care and outpatient care, shaping therapeutic selection and intensity of clinical oversight. Finally, patient demographics differentiate adult, geriatric, and pediatric patients, each subgroup presenting unique therapeutic priorities, safety considerations, and regulatory pathways. Considering segmentation holistically enables stakeholders to tailor development plans, commercial strategies, and care delivery models to distinct clinical and operational realities.

Regional dynamics and strategic imperatives across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence access, research, and commercialization of schizophrenia therapies

Regional dynamics significantly influence how schizophrenia therapies are developed, approved, reimbursed, and adopted, and understanding these distinctions is essential for effective global strategies. In the Americas, clinical development infrastructure, a relatively mature payer landscape, and growing acceptance of digital health solutions support rapid uptake of new therapeutic modalities; however, access disparities across urban and rural settings and variability in community-based services require tailored distribution and engagement strategies.

In Europe, Middle East and Africa, regulatory pathways and healthcare funding models vary considerably across countries, producing a mosaic of access conditions and adoption timelines. Many jurisdictions emphasize health technology assessments and comparative effectiveness evidence, which places a premium on robust real-world data and long-term outcomes research. Additionally, capacity constraints in certain markets underscore the importance of training programs and partnerships with local providers to ensure appropriate deployment of complex therapies.

Across Asia-Pacific, rapid investment in clinical research, strong manufacturing capabilities, and increasing digital health uptake create fertile conditions for both innovation and scale, but market entry strategies must account for diverse regulatory expectations, reimbursement environments, and cultural considerations related to mental health. Taken together, regional insight suggests that a differentiated approach to regulatory engagement, evidence generation, and commercial rollout, sensitive to local clinical practices and health system priorities, will produce the most sustainable patient access and commercial outcomes.

Key company strategies and competitive dynamics in schizophrenia therapeutics emphasizing partnerships, pipeline diversification, digital integration, and patient engagement strategies

Competitive dynamics among companies operating in the schizophrenia therapeutics space are driven by innovation in modality, strategic partnerships, and a growing emphasis on integrated care solutions. Established biopharmaceutical firms continue to invest in molecule optimization, formulation improvements, and lifecycle management for legacy therapies, while emerging biotechnology companies focus on novel mechanisms of action and biomarker-driven candidates that address treatment-resistant populations.

Concurrently, technology companies and digital health entrants are developing adjunctive platforms for symptom monitoring, adherence support, and cognitive remediation, which expands the competitive set and creates opportunities for cross-sector collaborations. Contract research organizations and specialized manufacturing partners play a critical role in accelerating time to clinic for novel modalities, offering expertise in formulation scale-up and regulatory filings. Business models increasingly reflect a blend of licensing, co-development, and strategic acquisitions, enabling firms to combine complementary capabilities and de-risk development pathways.

From a commercial standpoint, companies prioritize evidence generation that demonstrates meaningful functional benefits, engages payers through outcomes-based agreements, and builds robust patient support programs to improve persistence and satisfaction. Leadership teams that align R&D priorities with real-world clinical needs, and that invest in scalable commercialization engines and provider education, will be well positioned to capture value while advancing patient outcomes.

Actionable recommendations for industry leaders to accelerate innovation, ensure supply resilience, demonstrate value to payers, and enhance patient outcomes in schizophrenia care

Industry leaders must pursue a set of coordinated actions to convert scientific advances into durable clinical and commercial gains. First, organizations should prioritize investments in long-acting formulations and combination approaches that improve adherence and reduce relapse, while concurrently developing rigorous evidence packages that highlight functional outcomes valued by clinicians and payers. Second, leaders should embed digital tools into development and care pathways to support remote monitoring, early relapse detection, and personalized adherence interventions, thereby enhancing continuity of care across settings.

Third, supply chain resilience must be elevated to a strategic priority through supplier diversification, regional manufacturing partnerships, and contingency planning to mitigate the kinds of disruptions that affect availability and patient care. Fourth, commercial teams should engage payers early, leveraging real-world evidence and health economic modeling to negotiate reimbursement frameworks that reward long-term value and reduced acute care utilization. Fifth, cultivating collaborative relationships with academic centers, patient advocacy groups, and behavioral health providers will accelerate the translation of innovations into routine practice and ensure that interventions respond to lived experience.

Finally, organizations should adopt adaptive regulatory and clinical development strategies that use biomarkers, adaptive designs, and pragmatic endpoints to demonstrate benefit efficiently. By aligning these actions across R&D, commercial, and operational functions, leaders can both enhance patient outcomes and sustain competitive differentiation in a complex therapeutic landscape.

Robust research methodology detailing primary and secondary approaches, stakeholder interviews, clinical evidence synthesis, and data validation techniques used in this analysis

The analysis underpinning this executive summary relied on a mixed-methods research approach that blended qualitative insights with systematic evidence synthesis to ensure robustness and relevancy. Primary research included structured interviews with clinicians, payer representatives, clinical operations leaders, and patient advocates to surface frontline challenges, adoption barriers, and priorities for evidence generation. These conversations informed the framing of key questions and highlighted where supplementary data collection would be most valuable.

Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and product labeling to map therapeutic mechanisms, safety signals, and approval pathways. Additionally, trial activity and pipeline intelligence were examined to identify modality trends and development bottlenecks. Data triangulation across these sources supported cross-validation of findings and helped reconcile discrepancies between stakeholder perspectives and published evidence.

Analytical rigor was ensured through predefined inclusion criteria, quality appraisal of evidence sources, and iterative review cycles with clinical experts to validate interpretations. Limitations were acknowledged explicitly, including variability in regional data availability and evolving regulatory contexts, and sensitivity analyses were applied where appropriate to test assumptions. Overall, this methodology produced a balanced, actionable view of the schizophrenia therapeutics landscape that supports strategic decision making.

Concluding insights synthesizing clinical, commercial, and regulatory trends to guide strategic decision making and prioritize patient-centric therapeutic development in schizophrenia

In conclusion, the schizophrenia therapeutics landscape is characterized by scientific innovation, shifting care models, and complex commercial dynamics that together create both opportunities and responsibilities for stakeholders. Advances in pharmacology, digital health, and psychosocial interventions offer tangible prospects for improving symptom control and functional recovery, yet sustained progress depends on coordinated evidence generation, adaptive regulatory engagement, and patient-centered service delivery.

Moreover, external pressures such as supply chain disruptions and policy changes underscore the need for strategic resilience and operational agility. Organizations that integrate diverse modalities, demonstrate real-world value, and cultivate partnerships across the healthcare ecosystem will better navigate uncertainty while expanding access to effective care. Ultimately, a focus on outcomes that matter to patients-cognitive function, social integration, and long-term stability-will serve as the touchstone for successful innovation and equitable implementation, guiding future investments and collaborative efforts across the field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of personalized pharmacogenomic approaches in schizophrenia treatment pipelines
  • 5.2. Rapid adoption of digital therapeutics and AI-enabled monitoring platforms for relapse prevention
  • 5.3. Growing emphasis on long-acting injectable formulations to improve patient adherence rates
  • 5.4. Expansion of novel glutamate receptor modulators for treatment-resistant schizophrenia populations
  • 5.5. Increasing investment in anti-inflammatory agents targeting neuroinflammation in schizophrenia
  • 5.6. Integration of real-world evidence studies to support label expansions and reimbursement decisions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Schizophrenia Therapeutics Market, by Type

  • 8.1. Non-Pharmacological Therapies
    • 8.1.1. Cognitive-Behavioral Therapy (CBT)
    • 8.1.2. Electroconvulsive Therapy (ECT)
    • 8.1.3. Family Therapy
  • 8.2. Pharmacological Therapies
    • 8.2.1. Injectable Medications
    • 8.2.2. Oral Medications

9. Schizophrenia Therapeutics Market, by Therapeutic Class

  • 9.1. Antipsychotics
    • 9.1.1. First-Generation Antipsychotics
    • 9.1.2. Second-Generation Antipsychotics
  • 9.2. Mood Stabilizers
  • 9.3. Selective Serotonin Reuptake Inhibitors

10. Schizophrenia Therapeutics Market, by Mechanism of Action

  • 10.1. Dopamine Receptor Antagonists
  • 10.2. Glutamate Modulators
  • 10.3. Serotonin Dopamine Activity Modulators

11. Schizophrenia Therapeutics Market, by Formulation Type

  • 11.1. Inserts and Patches
  • 11.2. Liquid Solutions
  • 11.3. Solid Tablets

12. Schizophrenia Therapeutics Market, by End Users

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Mental Health Clinics
  • 12.4. Research Institutes

13. Schizophrenia Therapeutics Market, by Patient Settings

  • 13.1. Inpatient Care
  • 13.2. Outpatient Care

14. Schizophrenia Therapeutics Market, by Patient Demographics

  • 14.1. Adult Patients
  • 14.2. Geriatric Patients
  • 14.3. Pediatric Patients

15. Schizophrenia Therapeutics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Schizophrenia Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Schizophrenia Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. AbbVie Inc.
    • 18.3.2. Acadia Pharmaceuticals Inc.
    • 18.3.3. Alkermes Plc
    • 18.3.4. Amneal Pharmaceuticals, LLC
    • 18.3.5. Astellas Pharma Inc.
    • 18.3.6. AstraZeneca plc
    • 18.3.7. BioXcel Therapeutics, Inc.
    • 18.3.8. Boehringer Ingelheim International GmbH
    • 18.3.9. Bristol Myers Squibb Company
    • 18.3.10. Cipla Limited
    • 18.3.11. Delpor, Inc.
    • 18.3.12. Dr. Reddy's Laboratories Ltd.
    • 18.3.13. Eli Lilly and Company
    • 18.3.14. Gedeon Richter Plc
    • 18.3.15. GlaxoSmithKline plc.
    • 18.3.16. Glenmark Pharmaceuticals Limited
    • 18.3.17. Johnson & Johnson Services, Inc.
    • 18.3.18. Lundbeck A/S
    • 18.3.19. Lupin Limited
    • 18.3.20. Luye Pharma Group Ltd
    • 18.3.21. Lyndra Therapeutics Inc
    • 18.3.22. Meiji Holdings Co., Ltd.
    • 18.3.23. Merck & Co., Inc.
    • 18.3.24. Neurocrine Biosciences, Inc.
    • 18.3.25. Novartis AG
    • 18.3.26. Otsuka Holdings Co., Ltd.
    • 18.3.27. Pfizer Inc.
    • 18.3.28. Reviva Pharmaceuticals Holdings, Inc.
    • 18.3.29. Sanofi S.A
    • 18.3.30. Sumitomo Pharma Co., Ltd.
    • 18.3.31. Sun Pharmaceutical Industries Limited
    • 18.3.32. Takeda Pharmaceutical Company Limited
    • 18.3.33. Teva Pharmaceutical Industries Ltd.
    • 18.3.34. Torrent Pharmaceuticals Ltd.
    • 18.3.35. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)

TAB